| 1 | ^(68)Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy显示文摘Objective:To evaluate the use of Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography(^(68)Ga-PSMA PET/CT),compared with conventional CT abdomen/pelvis(CTAP)and whole body single photon emission CT bone scan(BS),for detection of local or distant metastasis following biochemical failure/recurrence in post-prostatectomy patients.Methods:We conducted a review of our prospectively maintained,institutional database to identify 384 patients with post-prostatectomy biochemical failure/recurrence who underwent PSMA PET/CT,CTAP and BS from February 2015 to August 2017 in Nepean Hospital,tertiary referral centre.The results of the three imaging modalities were analysed for their ability to detect local recurrence and distant metastases.PSMA PET/CT and CTAP imaging were separately performed on the same day and the BS was performed within several days(mostly in 24 h).Difference in detection rates was determined between the modalities and the Chi square test was used to determine significance.Results:A total of 384 patients were identified with a median prostate-specific antigen(PSA)of 0.465 ng/mL(interquartile range =0.19-2.00 ng/mL).Overall,PSMA PET/CT was positive for 245(63.8%)patients whereas CTAP and BS were positive in 174 patients(45.3%).A total of 98 patients(25.5%)had local or distant metastasis detected on PSMA only,while 20 patients(5.2%)had recurrences detected on CTAP but not on PSMA PET/CT.Conclusion:The use of PSMA PET/CT has a higher detection rate of predicted local or distant metastasis compared to CTAP and BS in the staging of patients with biochemical recurrences after radical prostatectomy. | Yuigi Yuminaga Chris Rothe Jonathan Kam Kieran Beattie Mohan Arianayagam Chuong Bui Bertram Canagasingham Richard Ferguson Mohamed Khadra Raymond Ko Ken Le Diep Nguyen Celi Varol Matthew Winter | 2021 | Asian Journal of Urology2021，8，2： | 1 |
| 2 | Management of Hypertension:JNC 8 and Beyond显示文摘Hypertension is a leading risk factor for cardiovascular disease,the leading cause of death and morbidity in our society and on a global scale.Major components of cardiovascular disease include stroke,coronary artery disease,heart failure,and chronic kidney disease,in all of which hypertension plays a major role.The risk of these complications increases directly and linearly with systolic blood pressure starting at 115 mmHg.Although usually asymptomatic,hypertension is readily detectable on physical examination and is amenable to both lifestyle modifi cation and pharmacologic treatment in most patients.However,large proportions of the hypertensive population remain undetected and undertreated.Numerous guidelines have been issued during the past few decades to promote detection and optimal therapy.Despite the increase in risk with systolic blood pressure greater than 115 mmHg,the generally accepted threshold for diagnosis and treatment has been systolic blood pressure greater than 139 mmHg and diastolic blood pressure greater than 80 mmHg because until recently treatment to lower levels has been associated with an unfavorable relation between clinical benefi t and harm.In the past several years,new guidelines,advisories,commentaries,and clinical trials have provided evidence for a potential change in current recommendations for the management of hypertension.In this regard,the long-awaited eighth report of the Joint National Committee on the Prevention,Detection,Evaluation,and Treatment of High Blood Pressure recommended patients older than 60 years be treated to a systolic blood pressure of less than 150 mmHg,which has generated considerable controversy and caution.The striking fi ndings of the Systolic Blood Pressure Intervention Trial(SPRINT)have received considerable attention because of the demonstration that intensive therapy to a target systolic blood pressure below 120 mmHg decreases cardiovascular mortality and morbidity more than less intensive treatment to a target systolic blood pressure below 140 mmHg,but this approach is not fully generalizable because the trial excluded patients younger than 50 years and those with diabetes and prior stroke.This article addresses major issues in the management of hypertension,including those in the seventh and eight reports of the Joint National Committee on the Prevention,Detection,Evaluation,and Treatment of High Blood Pressure and subsequent studies,considering maintenance of prior standards as well as the potential application of important new fi ndings. | Ezra A.Amsterdam Sandhya Venugopal Jonathan Bui Balasingam Thevakumar Angela Thinda Sabrina Virk William J.Bommer Aman Khullar Gagan Singh | 2016 | Cardiovascular Innovations and Applications2016，，B09： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员